TrianglePolatuzumab Vedotin (NCT06594939)
Polatuzumab Vedotin trial for Diffuse Large B Cell Lymphoma (DLBCL) (NCT06594939). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 70 or older with untreated CD20-positive diffuse large B-cell lymphoma, stage II bulky, III, or IV. Ages 70–74 must meet frailty criteria.
The idea: mosunetuzumab connects T cells to lymphoma; polatuzumab delivers chemotherapy to targeted cells. Both join cyclophosphamide, doxorubicin, and prednisone with split chemotherapy dosing. After two cycles, negative PET and residual-disease tests allow four cycles instead of six. Researchers measure complete responses.
This phase 2 study plans 31 patients. Nirav Shah leads at the Medical College of Wisconsin in Milwaukee, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.